Tris Pharma Expands ADHD Portfolio With Acquisition Of NextWave Pharmaceuticals

Full integrated pharmaceutical company Tris Pharma, Inc. (Tris) recently acquired NextWave Pharmaceuticals (NextWave). NextWave—a Pfizer subsidiary—brings to Tris its two Attention Deficit Hyperactivity Disorder (ADHD) treatments, expanding its portfolio of ADHD treatments.

The two aforementioned NextWave ADHD treatments include Quillivant XR and QuilliChew ER. Quillivant XR is a central nervous system stimulant used to treat ADHD, while QuilliChew ER is the first and only once-daily, long-lasting chewable methylphenidate tablet for the treatment of ADHD in children six years and above.

Tris Pharma is a fully integrated pharmaceutical company focused on the development of innovative medicines that . . .